血友病基因治疗监测最小数据集推荐:国际血栓与止血学会科学标准化委员会基因治疗工作组通讯
国际血栓与止血学会(ISTH)科学标准化委员会基因治疗工作组发布血友病基因治疗监测最小数据集(GT-MDS),旨在促进数据收集并确保捕获近期欧洲药品管理局提及的最相关数据及已知和未知安全性与有效性参数。GT-MDS分为3个部分,包含常规基因治疗随访期间6个主题的精简列表,保持数据点数量少但允许快速独立的数据评估。
要点
- GT-MDS分为3个部分,包含常规基因治疗随访期间6个主题的精简列表。
- GT-MDS保持数据点数量少,但允许快速和独立的数据评估。
- GT-MDS报告不应丢失的最小相关信息,所有接受基因治疗的患者必须收集。
核心结论
- GT-MDS报告了不应丢失的最小相关信息,所有接受基因治疗的患者必须收集。
- 基因治疗登记处和最小数据集的实施增强并提升了全球层面的数据收集。
研究设计与样本
- 国际血栓与止血学会(ISTH)科学标准化委员会基因治疗工作组发布的通讯文件。
主要发现
- GT-MDS分为3个部分,包含常规基因治疗随访期间6个主题的精简列表。
- GT-MDS保持数据点数量少,但允许快速和独立的数据评估。
- 世界血友病联盟基因治疗登记处数据集由世界血友病联盟、国际血栓与止血学会和其他组织包括行业合作伙伴于2020年制定,是全面的。
关键数值与推荐
- 国际血栓与止血学会已确定一个最小有效性和安全性数据集,纳入世界血友病联盟基因治疗登记处,应在国家层面针对每位接受基因治疗产品的患者在特定时间点收集。
- GT-MDS旨在促进数据收集,并确保捕获近期欧洲药品管理局提及的最相关数据及最已知和未知的安全性和有效性参数。
- 最小数据集的概念不是创建新的数据集,而是确定应始终包括的关键和基本主题的子集。
临床怎么用
- GT-MDS报告不应丢失的最小相关信息,所有接受基因治疗的患者必须收集。
- 基因治疗登记处和最小数据集的实施增强并提升了全球层面的数据收集。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Independent data collection is crucial in addressing the challenges associated with gene therapy for hemophilia, which is a promising treatment option but requires careful monitoring and management of short-term and potential long-term safety concerns. The International Society on Thrombosis and Haemostasis has identified a minimum efficacy and safety data set included in the World Federation of Hemophilia Gene Therapy Registry that should be collected on a national basis at specific time points for each patient who has been treated with the gene therapy products. This Gene Therapy Minimum Data Set (GT-MDS) was developed to facilitate data collection and to ensure capturing the most relevant data and most known and unknown safety and efficacy parameters recently cited by the European Medicine Agencies. The concept of assembling a minimum data set is not about creating a new data set but rather about identifying a subset of critical and essential topics that should always be included. The GT-MDS is structured into 3 sections and comprises an abridged list of 6 topics during routine gene therapy follow-up, keeping the number of data points low but allowing for rapid and independent data evaluation. The World Federation of Hemophilia Gene Therapy Registry data set, developed by the World Federation of Hemophilia, the International Society on Thrombosis and Haemostasis, and other organizations, including industry partners in 2020, is comprehensive. The GT-MDS reports the minimum relevant information that should not be lost and is mandatory to be collected for all patients who undergo gene therapy. Therefore, the implementation of the gene therapy registry and the minimum data set empowers and enhances data collection at a global level.
引用
- Miesbach W, Konkle B, Chowdary P, et al. Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy. J Thromb Haemost. 2024. PMID: 38242208. doi:10.1016/j.jtha.2023.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。